Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG953

—

a2aaed6f-d6c0-58e6-bd71-9986a89a3167

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • MITOTIC_SPINDLE+0.454
  • PROTEIN_SECRETION+0.413
  • E2F_TARGETS+0.357
  • G2M_CHECKPOINT+0.332
  • OXIDATIVE_PHOSPHORYLATION+0.293
  • NOTCH_SIGNALING+0.258
  • PI3K_AKT_MTOR_SIGNALING+0.219
  • HEME_METABOLISM+0.140
  • ADIPOGENESIS+0.062
  • WNT_BETA_CATENIN_SIGNALING+0.045

Top 10 suppressed

  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.489
  • TNFA_SIGNALING_VIA_NFKB-0.458
  • ALLOGRAFT_REJECTION-0.436
  • INFLAMMATORY_RESPONSE-0.432
  • PANCREAS_BETA_CELLS-0.429
  • INTERFERON_GAMMA_RESPONSE-0.407
  • INTERFERON_ALPHA_RESPONSE-0.384
  • HEDGEHOG_SIGNALING-0.366
  • P53_PATHWAY-0.359
  • HYPOXIA-0.350

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1SJEPD031592_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.884
2SJEPD030469_D1.RNA-Seq
medullo-epn-umap@date-based
EPNSupratentorial EPN0.876
3MDT-AP-3311
medullo-epn-umap@date-based
MedMedulloblastoma0.871
4BS_J8G4SH4Z
medullo-epn-umap@date-based
MedMedulloblastoma0.864
5SRR661290
brain-umap@2
GTEX—0.864
6MNG99
mng-umap@100
——0.859
7MDT-AP-0113
medullo-epn-umap@date-based
MedMedulloblastoma0.858
8BS_A46RDWGM
brain-umap@2
low-grade glioma—0.856
9BS_4CP4T22V
medullo-epn-umap@date-based
MedMedulloblastoma0.853
10MDT-AP-3021
medullo-epn-umap@date-based
MedMedulloblastoma0.852

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 13 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
MITOTIC_SPINDLE0.454Inavolisib— uncovered
PROTEIN_SECRETION0.413Remibrutinib— uncovered
E2F_TARGETS0.357Inavolisib— uncovered
G2M_CHECKPOINT0.332Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.293Remibrutinib— uncovered
NOTCH_SIGNALING0.258Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.219Inavolisib— uncovered
HEME_METABOLISM0.140Temsirolimus— uncovered
ADIPOGENESIS0.062Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.045Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.029Idelalisib— uncovered
UV_RESPONSE_DN0.028Inavolisib— uncovered
MYC_TARGETS_V10.019Inavolisib— uncovered